TandemAI has closed a $22 million Series A extension that will enable the company to advance its AI-driven drug discovery platform and expand its ability to serve a growing global client base. The financing includes participation from both new and existing investors, bringing the company’s total capital raised since its October 2021 founding to more than $80 million.
The company now employs more than 300 professionals and has built a fully integrated drug discovery engine that blends advanced AI models, physics-based computational methods, and extensive wet lab capabilities. This combination has yielded more than ten differentiated candidates that have either entered clinical development or are preparing to do so. TandemAI has also established partnerships with four of the world’s ten largest multinational pharmaceutical companies and has expanded its network to over 150 global partners and clients.
The new investment follows the company’s recent merger with Perpetual Medicines, a move that significantly expanded its capabilities across peptide and antibody-peptide conjugate discovery. The merger also added experienced drug development leaders, further strengthening TandemAI’s end-to-end expertise. With this additional funding, the company plans to invest heavily in the development of AI and computational physics models across multiple therapeutic modalities, while increasing wet lab capacity to meet the strong demand for its small molecule and peptide discovery programs.
TandemAI continues to position itself as a computation-first drug discovery company, delivering a technology stack that combines generative AI, physics-based modeling (including molecular dynamics and quantum mechanics), and a next-generation SaaS platform, TandemViz.
The company integrates these technologies with large-scale chemistry and biology labs to support every stage of the drug development process from target prediction to clinical candidate selection. This approach has garnered growing interest from biopharmaceutical organizations seeking faster, more efficient, and more reliable discovery pipelines.
KEY QUOTES:
“TandemAI has successfully executed on its approach to build and commercialize a powerful drug discovery platform by integrating AI and physics-based computational technologies with wet lab techniques.”
“With this funding, the company and its outstanding team are well positioned to grow its existing small molecule business and, with the recent merger with Perpetual Medicines, capitalize on the significant emerging opportunities in peptide and antibody-peptide conjugate discovery.”
Peter Zhao, Managing Director at V-Capital
“AI and advanced physics-based methods are now essential for drug discovery. TandemAI’s platform has notably enhanced R&D efficiency and success rates in small molecule and peptide drug discovery, driving rapid growth even during the pharmaceutical market downturn. We are pleased to support the company’s continued growth.”
KHK Fund
“This funding will support AI and computational physics-based model development for multiple modalities, as well as wet lab capacity expansion to accommodate our rapidly growing client base.”
Jeff He, Co-Founder and CEO of TandemAI
